Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucchini, Matteo, Bianco, Assunta, Del Giacomo, Paola, De Fino, Chiara, Nociti, Viviana, Mirabella, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307994/
https://www.ncbi.nlm.nih.gov/pubmed/32593961
http://dx.doi.org/10.1016/j.msard.2020.102323
Descripción
Sumario:The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.

Ejemplares similares